Rapamycin Results Timeline: What Studies Measured, and When

Rapamycin (sirolimus) has been studied across an unusually wide range of settings — organ transplantation, vascular anomalies, neurodegeneration, tuberous sclerosis complex, and companion-animal aging research. Because those settings differ so much, there is no single "rapamycin timeline." What exists instead is a set of published studies, each with its own measurement schedule. This page organises what researchers measured, and at which timepoints, in the verified literature cited below.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical decision or medication. Nothing here describes what any individual would experience, and no dosing, timing or protocol guidance is offered.

Why "How Long Does Rapamycin Take?" Has No Single Answer

The outcomes measured in rapamycin trials range from blood drug levels (measurable within days) to tumour recurrence and survival (measured over years). A drug level, a cardiac wall thickness measurement and a five-year recurrence rate are not the same kind of endpoint and do not appear on the same clock.

It is also worth noting up front that human healthspan or anti-aging trials of rapamycin remain limited. The largest published dataset in that space was observational rather than randomised: researchers evaluated off-label rapamycin use to promote healthspan across 333 adults and reported on self-described outcomes and adverse events in that cohort (GeroScience, 2023). Observational survey data of that kind cannot establish a timeline of effect the way a controlled trial can, and the paper's design reflects that limitation.

Timepoints Reported in Human Trials

Weeks: early safety and biomarker windows

Short human studies have generally asked whether rapamycin was tolerated and whether it reached relevant tissues, not whether long-term disease outcomes changed. A pilot phase 1 clinical trial of rapamycin treatment for Alzheimer's disease and related dementias administered treatment over an eight-week period and reported on safety, tolerability and biomarker measures in that window (Communications Medicine, 2025). The study was explicitly framed as a phase 1 pilot, meaning it was sized to examine feasibility and safety rather than to demonstrate cognitive change.

In amyotrophic lateral sclerosis, a randomized, double-blind, placebo-controlled trial of rapamycin ran an 18-week treatment period and assessed immunological and clinical outcomes over that span (Nature Communications, 2023). The researchers reported that the trial did not meet its primary outcome, which is an important reminder that a defined measurement window is not the same as a demonstrated benefit at that window.

Months: structural and lesion outcomes

Where the endpoint was a visible or measurable structure — a lesion, a tumour, a growth — study schedules extended into months. The observational-phase randomized PERFORMUS trial evaluated sirolimus for slow-flow malformations in children and used a 12-month observational phase design to assess lesion response (JAMA Dermatology, 2021). Lesion volume and clinical response measures of this kind require repeated imaging and clinical assessment over many months; they are not week-scale endpoints.

In tuberous sclerosis complex, a phase I study of preventative treatment with sirolimus reported safety and efficacy results from early-life treatment, framed as a phase I evaluation of whether preventative dosing was feasible and tolerated (Annals of the Child Neurology Society, 2024). Preventative designs in a developmental disorder necessarily measure outcomes over an extended follow-up rather than at a single early checkpoint.

Years: recurrence and survival endpoints

The longest published human timelines come from transplant oncology. A single-arm, multicenter, prospective study examined the efficacy and safety of a sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma, reporting recurrence and survival outcomes as the endpoints of interest (Hepatobiliary & Pancreatic Diseases International, 2022). Endpoints such as recurrence-free survival are measured across years of follow-up, and no meaningful readout exists at four, eight or twelve weeks in that design.

Summary Table: Study Type and Measurement Window

Where Human Data Is Thin — And What Preclinical Timelines Showed

For the questions most often asked about rapamycin and aging, controlled human timeline data is genuinely sparse. The available human healthspan dataset was a survey of off-label users rather than a randomised trial (GeroScience, 2023). The remainder of the aging-relevant evidence is preclinical or veterinary, and is labelled as such throughout this section.

Veterinary trials: cats and dogs

In cats, the RAPACAT trial tested delayed-release rapamycin in subclinical feline hypertrophic cardiomyopathy and reported that treatment halted progression of left ventricular hypertrophy (Journal of the American Veterinary Medical Association, 2023). That endpoint — change in cardiac wall measurements — depends on serial echocardiography over months, not on any short-term subjective readout.

In dogs, the Test of Rapamycin in Aging Dogs (TRIAD) was described as a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project (GeroScience, 2025). The published paper set out study design and rationale; a design paper establishes the intended measurement schedule but does not itself report outcome results.

Rodent work: exercise adaptation and cardiac mechanics

Rodent studies have examined whether rapamycin interferes with adaptations that take weeks to develop. Researchers reported that rapamycin did not compromise exercise-induced muscular adaptations in female mice (Aging Cell, 2025) — a question that only becomes answerable after a training period long enough for adaptation to occur.

On the cardiac side, a preprint reported that late-life rapamycin treatment enhanced cardiomyocyte relaxation kinetics and reduced myocardial stiffness in an aged-animal model (bioRxiv, 2023). As a preprint, that work had not completed peer review at the time of posting, which is relevant to how much weight its timeline carries.

Immunological timelines have also been examined: one study reported that rapamycin improved long-term T-cell memory and the protective efficacy of a tuberculosis subunit vaccine (Microbial Pathogenesis, 2024). "Long-term memory" is by definition an endpoint assessed well after the intervention period rather than during it.

Dose–Response and Schedule: Why Timing Is Not Linear

A recurring theme in the rapamycin literature is that more exposure did not straightforwardly mean more effect. Researchers described biphasic rapamycin effects in lymphoma and carcinoma treatment, reporting that outcomes differed depending on the exposure conditions studied (Cancer Research, 2017). A biphasic relationship means that a timeline built from one exposure condition may not transfer to another — one reason cross-study comparison of "when effects appeared" is difficult.

Formulation mattered too. The feline cardiomyopathy trial specifically used a delayed-release rapamycin preparation (JAVMA, 2023), while transplant literature used sirolimus in a conversion protocol context (HBPD Int, 2022). Different formulations and administration schedules generate different exposure patterns, and the measurement schedules were built around those differences.

Safety Timepoints: What Studies Report

Adverse events in rapamycin research were typically monitored continuously rather than at a single checkpoint, and the reporting reflects each trial's duration.

• The ALS trial was a randomized, double-blind, placebo-controlled design with safety assessed across its 18-week treatment period alongside its clinical and immunological outcomes (Nature Communications, 2023).
• The Alzheimer's pilot was a phase 1 trial, meaning safety and tolerability over the eight-week period were among its primary concerns (Communications Medicine, 2025).
• The tuberous sclerosis complex study reported phase I safety results for preventative sirolimus treatment (Annals of the Child Neurology Society, 2024).
• The liver transplant conversion study reported efficacy and safety together in its single-arm prospective design (HBPD Int, 2022).
• The 333-adult off-label evaluation reported adverse events described by that cohort, but as an observational dataset without a control group (GeroScience, 2023).

Rapamycin is an immunosuppressant used in transplant medicine, and safety monitoring in the cited trials was structured accordingly. Readers evaluating any of this should do so with a licensed physician.

How to Read a Rapamycin Timeline Critically

1. Match the endpoint to the clock. Recurrence and survival endpoints were measured over years (PMID 34583911); safety and biomarker endpoints were measured over weeks (PMID 40394335).
2. Check whether the study reported results at all. The TRIAD publication described study design and rationale rather than outcomes (PMID 39951177).
3. Check whether the primary outcome was met. The ALS trial reported that its primary outcome was not met despite a fully defined 18-week schedule (PMID 37591957).
4. Keep species separate. Feline (PMID 37495229) and murine (PMID 40704394) timelines were not human timelines.
5. Watch for non-linear exposure effects, as in the biphasic effects researchers described in cancer models (PMID 27737881).

Bottom Line

Across the verified literature, rapamycin measurement windows spanned eight weeks in a dementia pilot (PMID 40394335), 18 weeks in an ALS trial where the primary outcome was not met (PMID 37591957), 12 months in a paediatric vascular malformation trial (PMID 34524406), and multi-year follow-up in transplant oncology (PMID 34583911). Controlled human healthspan timeline data remained absent from this set; the closest human dataset was observational (PMID 37191826), with aging-relevant controlled work sitting in veterinary and rodent models. For broader background, see the related overview at /learn/rapamycin/.

References

• Delayed-release rapamycin halts progression of left ventricular hypertrophy in subclinical feline hypertrophic cardiomyopathy: results of the RAPACAT trial (Journal of the American Veterinary Medical Association, 2023)
• Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis (Nature Communications, 2023)
• Evaluation of off-label rapamycin use to promote healthspan in 333 adults (GeroScience, 2023)
• Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: A single-arm, multicenter, prospective study (Hepatobiliary & Pancreatic Diseases International, 2022)
• Rapamycin treatment for Alzheimer's disease and related dementias: a pilot phase 1 clinical trial (Communications Medicine, 2025)
• Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial (JAMA Dermatology, 2021)
• Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results (Annals of the Child Neurology Society, 2024)
• Rapamycin Does Not Compromise Exercise-Induced Muscular Adaptations in Female Mice (Aging Cell, 2025)
• Rapamycin improves the long-term T-cell memory and protective efficacy of tuberculosis subunit vaccine (Microbial Pathogenesis, 2024)
• Late-life Rapamycin Treatment Enhances Cardiomyocyte Relaxation Kinetics and Reduces Myocardial Stiffness (bioRxiv, 2023)
• Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment (Cancer Research, 2017)
• Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project (GeroScience, 2025)